Literature DB >> 18240194

Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.

Adam M Huber1, Elizabeth M Dugan, Peter A Lachenbruch, Brian M Feldman, Maria D Perez, Lawrence S Zemel, Carol B Lindsley, Robert M Rennebohm, Carol A Wallace, Murray H Passo, Ann M Reed, Suzanne L Bowyer, Susan H Ballinger, Frederick W Miller, Lisa G Rider.   

Abstract

OBJECTIVE: To provide preliminary validation of the Cutaneous Assessment Tool (CAT), a new tool to assess cutaneous manifestations of juvenile dermatomyositis (DM), and to explore the clinical meaning of CAT scores.
METHODS: Children with juvenile DM (n = 113) were assessed at baseline and 7-9 months later (n = 94). Internal consistency, redundancy, construct validity, and responsiveness of the CAT were examined. CAT scores corresponding to ordinal global assessments were determined.
RESULTS: Item-total correlations ranged from 0.27-0.67 for activity lesions present in > or =10% of patients; item-domain and domain-total correlations ranged from 0.25-0.99. Cronbach's alpha was 0.79 for the CAT activity score and 0.74 for the CAT damage score. As predicted, the CAT activity score correlated strongly with both global disease activity and skin disease activity and moderately with the Childhood Myositis Assessment Scale, whereas the CAT damage score correlated moderately with the physician global disease and skin disease damage scores. Median CAT activity scores of 1, 7, 13, 18, and 31 corresponded to absent, mild, moderate, severe, and extremely severe skin disease activity, respectively. Median CAT damage scores of 0, 1, 2, and 5 correlated with the same descriptions of damage (severe and extremely severe combined).
CONCLUSION: Preliminary validation of the CAT demonstrated good internal consistency, nonredundancy, good construct validity, and appropriate responsiveness. The CAT is a comprehensive, semiquantitative assessment tool for skin disease in juvenile DM.

Entities:  

Mesh:

Year:  2008        PMID: 18240194     DOI: 10.1002/art.23340

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.

Authors:  Adam M Huber; Peter A Lachenbruch; Elizabeth M Dugan; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-03-15

3.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

4.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

5.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

6.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Authors:  Adam M Huber; Edward H Giannini; Suzanne L Bowyer; Susan Kim; Bianca Lang; Carol B Lindsley; Lauren M Pachman; Clarissa Pilkington; Ann M Reed; Robert M Rennebohm; Lisa G Rider; Carol A Wallace; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

Review 7.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Authors:  R Q Klein; C A Bangert; M Costner; M K Connolly; A Tanikawa; J Okawa; M Rose; S S Fakharzadeh; D Fiorentino; L A Lee; R D Sontheimer; L Taylor; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2008-07-04       Impact factor: 9.302

Review 9.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

Review 10.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.